INTRODUCTION
Substance use disorders (SUDs) are a major contributor to morbidity and mortality worldwide. 1 According to the United Nations, more than 200,000 deaths were attributable to SUDs in 2014. 2 Moreover, in 2015 over 20 million people in the U.S.
had an SUD, with <20% seeking treatment. 2 While several treatments are available (eg, behavioral and pharmacological therapies), relapse rates continue to be as high as 60%. 1 This suggests a need for further research to develop novel and more effective treatments. Neuromodulation techniques such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS) have been investigated as possible treatments for SUDs and may have promise in comparison to conventional pharmacotherapy and behavioral intervention strategies, and there have been several more selective reviews on this topic. [3] [4] [5] The purpose of this article is to provide a broad and critical review of currently available brain stimulation techniques (rTMS, tDCS, DBS) as treatment for SUDs, including a comparison of effect sizes for the various brain stimulation methods across SUD diagnoses.
Description of Contemporary Brain Stimulation Methods

Repetitive Transcranial Magnetic Stimulation (rTMS)
rTMS is a non-invasive brain stimulation method used to treat various neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, obsessive compulsive disorder, and chronic pain. 6 In 2008, rTMS was Food and Drug Administration (FDA) approved for the treatment of major depression in human subjects, offering a potential alternative to traditional pharmacotherapies, which may not be effective or well-tolerated. 6 rTMS involves the use of an electromagnetic coil held against the scalp, producing repetitive trains of magnetic pulses, resulting in a temporary magnetic field pulse in the coil that can be targeted to specific brain regions. 7, 8 This process has been shown to induce temporary electrical currents in localized cortical tissue, which can modulate cortical excitability. Studies have also demonstrated its ability to produce clinically significant and lasting neuroplasticity changes in targeted brain regions. 7, 8 rTMS stimulation parameters can vary significantly with respect to stimulus intensity, total number of pulses, and pulse frequencies.
However, ultimately these variations aim to personalize rTMS parameters and may improve inhibitory processes, which may be abnormal in SUDs (ie, impulsivity). As such, many investigators have used cortical inhibition paradigms with single or paired pulse TMS to index cortical inhibition and excitability effects. 10, 11 This review will focus on low frequency (LF) and high frequency (HF) rTMS, both of which provide therapeutic applications. LF rTMS (<1 Hz) has been shown to reduce neuronal firing rates and cortical excitability, whereas HF rTMS (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Hz) has demonstrated opposing effects. 7, 8 Furthermore, two robust rTMS adaptations compared to the conventional protocols have been emerging which use a theta burst stimulation (TBS) pattern. 12 This involves bursts of three pulses of stimulation at 50 Hz frequencies repeated every 200 ms. The first method is intermittent bursting frequency, also known as intermittent that burst stimulation (iTBS), which is applied to the cortex resulting in facilitating effects. The parameters involve a 2 second train of TBS repeated every 10 seconds for a total of 190 seconds (600 pulses). 12, 13 The other technique using continuous bursting frequency, also known as continuous theta burst stimulation (cTBS), induces transient long-term depression of behavior and inhibitory effects. This technique involves a 40 second train of uninterrupted TBS (600 pulses). 12, 14 rTMS is a promising treatment for neurological and psychiatric disorders, as this treatment method has minor side effects (ie, headache, dizziness) and is pain free, making it well-tolerated by most patients. 6 Additionally, rTMS is a costeffective alternative to other more expensive treatment methods (ie, electroconvulsive therapy). rTMS is a promising potential treatment for SUDs that is currently being investigated, although available research is preliminary. Twenty-eight studies were identified for this review, using rTMS as a potential treatment for SUDs, with a total of 788 participants receiving active or sham rTMS stimulation treatment. See Table 1 and Figure 1A .
Transcranial Direct Current Stimulation (tDCS)
tDCS is another non-invasive brain stimulation method involving two or more electrodes (ie, anodal, cathodal) placed on the scalp. 15 These electrodes facilitate delivery of a low intensity direct current at a constant rate to a targeted area of the brain. 16 tDCS protocols vary with respect to the current size and strength, electrode size and number, amount of contact medium used, and stimulation durations. 17 Similarly, as with the differing rTMS parameters, these factors alter the distribution of current crossing the scalp eventually to the brain.
tDCS stimulation produces a low intensity current (between 0.5 and 2.0 milliamps [mA] ) that allows for the modulation of resting membrane potential and cortical excitability in targeted brain regions through mechanisms of depolarization or hyperpolarization, depending on stimulation parameters. 18 The anodal electrode has been shown to increase cortical excitability, whereas the cathodal electrode has opposing effects. tDCS is a low cost, easily accessible, pain free stimulation method with minor side effects such as scalp irritation and itchiness and no recovery time requirement, thus making it well-tolerated treatment across patients. 15 Similar to rTMS, tDCS has been used to treat various neurological and psychiatric conditions such as Parkinson's disease, chronic pain, and major depression. 15 Although its mechanisms of action are not fully understood, tDCS may induce neurochemical changes in the targeted brain tissue, which extend beyond active stimulation periods. 18 tDCS is also currently being investigated as a potential treatment for SUD's in human participants. Twenty-three studies have been identified in which tDCS has been explored as a viable treatment option, with 677 participants having been exposed to active or sham stimulation. See Table 2 and Figure 1B .
Deep Brain Stimulation (DBS)
DBS is a third neuromodulation technique which has been used to treat disorders such as Alzheimer's disease, obsessivecompulsive disorder (OCD), and chronic pain. Unlike rTMS and tDCS, DBS involves an invasive surgical procedure, whereby varying numbers of electrodes are implanted directly into the brain, enabling continuous modulation of brain activity and subsequent changes in neuroplasticity. 19 It has also demonstrated the ability to regulate abnormal brain impulses occurring in specified cortical regions. DBS may be able to trigger neurotransmitter release in the brain, depending on the regions of electrode implantation. In comparison to TBS which activates or inhibits neurons with lower frequencies to targeted areas, DBS uses very high frequencies to block neural transmissions.
14 Once implanted into the individual's brain, DBS electrodes are connected to an implantable pulse generator (IPG), typically inserted in the chest wall, allowing for easy modulation of parameters and continuous stimulation at a designated frequency (>130 Hz). 19 Furthermore, due to its invasive nature, DBS may cause serious side effects associa-ted with surgical procedures, such as infection, seizure, and stroke. 19 Notably, once a patient has recovered from the original surgical procedure, DBS seems to be well-tolerated. The exact mechanisms by which DBS exerts its clinical effects remain unclear, however, the ability of DBS to directly manipulate neural circuits in reward pathways may target addictive behaviors. As such, DBS is being investigated as a possible treatment for SUDs. Nine studies investigating the use of DBS as treatment for SUDs have been identified, with 25 participants having received active or sham stimulation. See Table 3 and Figure 1C .
METHODS
A comprehensive literature search (by A.C. and K.K.) was conducted using PubMed and Google Scholar. Articles published after 2000 in peer-reviewed academic journals were included. A combination of key search terms was used to locate the articles for this review, including: non-invasive brain stimulation, repetitive transcranial magnetic stimulation, rTMS, transcranial direct current stimulation, tDCS, deep brain stimulation, DBS, addiction, substance use disorder, abuse, dependence, alcohol, tobacco, smoking, nicotine, cocaine, cannabis, amphetamines, opioids, treatment, therapy, craving, and consumption. Inclusion criteria also consisted of participants who met DSM-IV criteria for substance abuse or dependence, or DSM-5 criteria for substance use disorders. Only studies whose primary and/or secondary outcomes were related to substance use outcomes (ie, consumption, abstinence, craving, and withdrawal) or drug cue-induced neurophysiological/functional imaging changes were included in this review. This process yielded 69 studies, of which nine were excluded 14, [20] [21] [22] [23] [24] [25] [26] [27] that did not meet these criteria.
RESULTS
Repetitive Transcranial Magnetic Stimulation (rTMS) Alcohol
To date, nine studies [28] [29] [30] [31] [32] [33] [34] [35] [36] have investigated the potential efficacy of rTMS in the treatment of alcohol use disorder, with mixed results. Six studies 28, [32] [33] [34] [35] [36] examined the effects of multiple sessions of rTMS (10-20 sessions) targeting the dorsolateral prefrontal cortex (DLPFC) or medial prefrontal cortex (mPFC), using a randomized, sham controlled study design. Findings from all six studies demonstrated a significant decrease in alcohol-related cravings or consumption post-active rTMS treatment. However, three other studies [29] [30] [31] found opposing results: rTMS to the DLPFC did not have significant effects on alcohol craving or consumption. Notably, these studies involved fewer total rTMS treatment sessions, which may explain the lack of efficacy in these trials (Table 1) .
Tobacco
Eleven studies [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] were conducted to investigate the use of rTMS on tobacco use disorder (nicotine dependence). Apart from Li et al., 37 all studies demonstrated positive effects of rTMS, via reduction in nicotine cravings and/or overall cigarette consumption post-active stimulation compared to baseline and sham data. Nine studies [37] [38] [39] [40] [41] [42] [43] 45, 47 directed stimulation at either the left or the right DLPFC with a stimulation frequency of 1-20 Hz.
Rose et al. 46 applied 1 and 10 Hz rTMS stimulation to the superior frontal gyrus and motor cortex (sham condition), which demonstrated differential effects after smoking cue presentation. In the neutral cue condition, 10 Hz stimulation reduced craving significantly compared to both 1 Hz and sham conditions. Notably, craving was significantly increased in the 10 Hz condition with the presentation of smoking cues. 46 In contrast, Dinur Klein et al. 44 applied 1 and 10 Hz stimulation to the lateral prefrontal cortex and insula, resulting in a significant decline in consumption in the 10 Hz condition only.
Cocaine
Four studies [48] [49] [50] [51] investigated the effects of rTMS on craving for cocaine in dependent adult participants. The number of treatment sessions ranged from 1 to 12, with a frequency range between 5 and 20 Hz. Three [49] [50] [51] of these studies demonstrated positive results, with a significant reduction in craving for cocaine, with the exception of Bolloni et al. 48 who found no significant change in craving compared to sham, although long-term reduction in consumption was significant when considering time as a factor.
Methamphetamine
Thus far, there have been only three studies investigating rTMS for methamphetamine (MA) dependence. [52] [53] [54] Su et al. 52 applied five sessions of 10 Hz rTMS to the left DLPFC. Results indicated a significant reduction in cravings for MA compared to sham stimulation. Conversely, Li et al. 53 studied the effects of two sessions of rTMS in MA-dependent participants and demonstrated no significant impact of rTMS on craving or consumption of MA, compared to sham. 53 A third study by Liu et al. 54 studied the effects of five sessions of rTMS to the left or right DLPFC in both 1 and 10 Hz conditions compared to sham, with a significant reduction in cue-induced craving across all four stimulation conditions compared to sham.
Cannabis
A single study 55 investigated the use of rTMS on cannabis craving in a crossover, sham-controlled study, using a single session of 10 Hz stimulation to the left DLPFC in cannabisdependent participants. There were no significant reductions in craving scores between active and sham stimulation groups. 
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Transcranial Direct Current Stimulation (tDCS)
Alcohol Seven studies [56] [57] [58] [59] [60] [61] [62] have been conducted examining the effects of tDCS as a possible treatment for alcohol use disorder. Of these studies, six 56, 57, [59] [60] [61] [62] have demonstrated positive effects of tDCS on alcohol craving and/or consumption. Notably, in a study by Da Silva et al, 61 although craving was significantly attenuated in the active group, active tDCS resulted in a significant increase in relapse rates. Furthermore, one study 60 showed that although tDCS had no significant effect on attenuation of alcohol cravings or acute consumption, abstinence rates improved significantly at 6-month follow-up. Finally, a study by Nakamura-Palacios et al. 58 investigated the effects of neutral versus active cues on P3 amplitudes, with positive results. All studies varied on stimulation parameters, with no apparent pattern associated with either positive or non-significant results ( Table 2) .
Tobacco
Eight studies [63] [64] [65] [66] [67] [68] [69] [70] have examined the effects of tDCS on nicotine craving in dependent participants. All studies applied 2.0 mA stimulation for 15-30 minutes, except one by Falcone et al., 70 who used a stimulation intensity of 1.0 mA for 20 minutes. Five [64] [65] [66] 68, 70 of the aforementioned studies demonstrated positive effects on nicotine cravings and/or consumption, with significant reductions seen across participants. In contrast, three additional studies 63, 67, 69 observed no significant effect on craving or consumption of tobacco; two of these studies 67, 69 used a single stimulation session of tDCS, and the third 63 used a sample that consisted of patients with a diagnosis of schizophrenia or schizoaffective disorder, which may have contributed to the negative findings, as this population tends to be more highly nicotine dependent than non-psychiatric populations.
Cocaine
Five studies [71] [72] [73] [74] [75] have been conducted to understand the effects of tDCS on cocaine use disorder. Two studies 73, 74 examined the effects of tDCS on craving in this population using 2 mA stimulation for 20 minutes with positive results (Table 2 ). Gorini et al. 75 applied contralateral stimulation of 1.5 mA to participants with cocaine dependence and controls, finding significant decreases in indices of risk-taking behavior. Finally, tDCS to the bilateral DLPFC reduced anterior cingulate activation 71 and increased P3 physiological responses.
72
Methamphetamine Shahbabaie et al. 76 conducted a study using one session of 2.0 mA tDCS to the right DLPFC over 20 minutes in MAdependent participants. While a significant reduction in acute MA cravings was observed at rest, an increase in cue-induced MA cravings was reported 20 minutes post-treatment.
Opioids
A single study conducted by Wang et al. 77 investigated the effects of tDCS on craving scores of 20 heroin-dependent participants. In contrast to other tDCS research in SUD's, this bilateral stimulation was applied to the fronto-temporal-parietal area (FTP). Despite this difference, investigators observed a significant decline in heroin craving, which persisted with the presentation of heroin-related cues. 77 
Cannabis
A study by Boggio et al. 78 investigated the use of tDCS as a treatment for cannabis use disorder. Twenty-five chronic cannabis users received 10 Hz stimulation to either the left or right DLPFC. Results from this study showed that stimulation of the right DLPFC, but not the left, was associated with a decline in cannabis-related craving.
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Deep Brain Stimulation (DBS) Alcohol
Three studies [79] [80] [81] investigated the effects of DBS on alcohol use disorder, applying active stimulation to the nucleus accumbens, showing a decrease in alcohol consumption or craving levels across studies (Table 3) .
Tobacco
There have been two studies 82, 83 investigating the use of DBS on cigarette smoking and nicotine-dependence targeting the nucleus accumbens. Kuhn et al. 83 conducted a study in nicotine craving and cigarette consumption. Of 10 nicotine-dependent participants, three quit smoking altogether, while the remaining seven participants demonstrated a significant decline in cravings and consumption. In another study, 82 active DBS significantly reduced craving and consumption of cigarettes in a single subject who originally underwent DBS treatment for refractory OCD.
Cocaine
A single study 84 investigated the effects of DBS on cocaine use in a single participant. Active DBS targeting the nucleus accumbens significantly reduced both craving and consumption of cocaine in this dependent participant.
Opioids
Recently, three studies [85] [86] [87] have examined the effects of active DBS on opioid consumption or craving in heroindependent participants, targeting the nucleus accumbens. All three studies demonstrated a significant decline in consumption and/or cravings and an increase in abstinent participants.
DISCUSSION
This article reviews current research on available neuromodulation techniques (rTMS, tDCS, DBS), and their potential safety and efficacy across a broad range of SUDs. Findings were mixed across all three stimulation methods, which may in part, be due to the variation in stimulation parameters (ie, frequency, intensity, duration of treatment, brain regions stimulated), differences in SUDs, the severity of these SUDs between participants in each study, as well as heterogeneity in the populations studied, including the presence of co-occurring psychiatric disorders. With respect to effects of brain stimulation observed between SUDs, commonalities between rTMS and tDCS emerged. Studies utilizing rTMS observed promising findings in trials conducted in nicotine or stimulant (cocaine, methamphetamine) dependent samples, with 10/11 [37] [38] [39] [40] [41] [42] [43] [44] [45] 47 and 5/7 [49] [50] [51] [52] 54 positive studies, respectively in domains of craving and/or consumption. Moreover, in alcoholdependent participants, 6/9 studies 28,32-36 suggested reductions in alcohol craving and/or consumption after active rTMS treatment. Effect sizes (Cohen's d) for rTMS on alcohol (À0.07-2.99), tobacco (À0.40-4.42), methamphetamine (À0.20-2.78), and cocaine (À1.82-3.58) were promising but highly variable, consistent with the (methodological) heterogeneity of the published studies (Table 1) . Similarly, tDCS demonstrated comparable efficacy to rTMS in the treatment of nicotine and stimulant dependence: 5/8 studies [64] [65] [66] 68, 70 in nicotine dependence and 3/6 studies 73, 74, 76 conducted in stimulant dependence (cocaine, methamphetamine) had positive study findings in measures of craving and/or consumption. This was further supported with medium to large effect sizes ( 
77,78
Finally, DBS trials were promising with positive results across all nine reviewed studies that used this technique in alcohol, nicotine, stimulant, and opioid-dependent samples. Nonetheless, available data with DBS is limited to case series so the ability to calculate resultant effect sizes is limited (Table 3) , and further research is required to validate these findings, using larger sample sizes. Sample sizes of the DBS studies are very low (ranging 1-10; averaging 3.3 per study). These studies were primarily case series, and caution should be used when interpreting this data.
Findings Based on Stimulation Parameters
Stimulation parameters (ie, frequency, duration, brain region, and sample size/demographics) between and within the three brain stimulation methods also warrants comment. First, both rTMS and tDCS appear to be most effective when delivered using repeated versus single administration sessions, and these effects may vary as a function of treatment duration (including number of pulses, inter-stimulus intervals, and frequency of stimulation sessions). Further, the tDCS studies across the various SUDs, demonstrated that longer duration of treatment sessions (>10 minutes) had the most promising results. Moreover, the majority of positive studies utilized high-frequency (HF; >10 Hz) rTMS stimulation parameters (>10 Hz) in SUDs, while those using lowfrequency (LF; <10 Hz) rTMS stimulation were associated with less promising outcomes. Second, the effect of bilateral versus unilateral stimulation, as well as which brain region was targeted, appeared to have differential and distinctive effects. In rTMS and tDCS, nearly all studies conducted in treatment of SUDs targeted the left or right DLPFC. Exceptions to these brain targets for stimulation included two rTMS studies targeting the mPFC. 32, 33 Furthermore, Dinur-Klein et al. 44 used rTMS to target the lateral prefrontal cortex and insula, while Rose et al. 46 targeted the motor cortex and superior frontal gyrus. Two tDCS studies 68, 77 targeted the bilateral fronto-temporal-parietal area (FTP), with positive findings post-treatment, while a third study targeted the IFG. 57 Despite variation in brain region targets, these studies all had positive outcomes for drug craving and/or consumption. However, based on both the number of studies conducted and the magnitude of effect sizes calculated, specifically targeting the right (vs. left) DLPFC was associated with the most promising treatment outcomes. With regards to DBS, all studies to date have targeted the nucleus accumbens (NAc), which is also an area of the brain associated with reward pathway in SUDs. Therefore, the importance of targeting regions of the brain relating to the reward pathway is supported with the most efficacious results on cravings/consumptions. Nonetheless, more systematic and comparative studies are needed to determine dose effects of stimulus intensity, duration, and laterality. Moreover, few of the studies have followed subjects in the long-term (eg, 3-6 months post-treatment) to determine durability of neuromodulation effects. Additionally, comparative studies between brain regions and between treatment modalities have generally not been performed in a rigorous manner, and warrant further research.
Finally, since most of the published studies were preliminary (with total sample sizes <40), further research in larger patient samples using randomized, shamcontrolled designs are necessary to validate these brain stimulation methods for the treatment of SUDs. Notably, four studies involved the use of participants with a comorbid psychiatric condition. 32, 45, 63, 82 For instance, Wing et al. 45 used rTMS in a sample consisting of 15 participants with a primary diagnosis of schizophrenia. Despite this comorbidity, cravings for nicotine decreased significantly across participants. As this vulnerable population is 2-3 times more likely to smoke cigarettes and tend to be more highly nicotine dependent, rTMS may be a promising treatment option for patients with schizophrenia and comorbid tobacco use disorder. 45 Another study by Smith 63 used tDCS in a sample of patients with schizophrenia and concurrent nicotine dependence, but found that five sessions of stimulation had no significant effect on craving or consumption in this group. Furthermore, a study by Ceccanti et al. 32 studied participants with co-occurring dysthymic disorder and alcohol use disorder, with positive results indicating a significant decline in consumption after ten sessions of active rTMS. Finally, Mantione 82 implemented DBS in a woman with treatment refractory OCD. While this effect was unintended, the participant saw a significant decline in craving and consumption of cigarettes after DBS stimulation. Therefore, co-occurring disorders (ie, schizophrenia, mood, and anxiety) may be important determinants of the efficacy of these stimulation techniques. Further studies are warranted to understand the potential differential effects of brain stimulation in co-occurring disorders.
Other Neuromodulation Modalities
While other neuromodulation methods such as Electroconvulsive therapy (ECT), Magnetic Seizure Therapy (MST), and Transcranial Electric Stimulation (TES) are used, studies examining their effects on SUDs in human subjects are extremely limited. A single study 88 has investigated the effects of ECT on methamphetamine use disorders in a single participant, with positive results on withdrawal induced delirium and craving scores.
88
Directions for Future Research
While research on brain stimulation methods for the treatment of SUDs has shown considerable promise, 3 are preliminary and further research is needed. Future research should aim to identify optimal stimulation parameters for all three stimulation methods (rTMS, tDCS, DBS) with specific regard to duration and total number of stimulation treatments, targeted brain region, stimulation frequency or intensity, and proximity between treatments (ie, four treatments over 2 days versus four treatments over 4 days). Additionally, investigations to understand the lasting effects of each stimulation treatment method and the potential necessity of maintenance treatment sessions are critical for prolonging treatment effects. Studies examining the effects of brain stimulation while participants are undergoing fMRI scanning may be beneficial to understand the changes in targeted brain regions during stimulation sessions.
Additionally, studies comparing brain stimulation methods in SUDs may be beneficial to understand differences in efficacy between techniques. Furthermore, studies investigating patients with polysubstance use disorders and cooccurring psychiatric disorders are warranted, as some 7.9 million individuals in 2015 had co-occurring SUDs and mental illness in the U.S. 1 Moreover, studies investigating the effects of brain stimulation in participants with polysubstance use may also be beneficial, as the use of only one substance is relatively uncommon. Finally, studies to understand the potential benefits of concurrent therapies (pharmacological, behavioral) used in combination with brain stimulation may increase a participant's chances of becoming abstinent. For example, Trojak 41 used rTMS in combination with nicotine replacement therapy (NRT) in the form of a patch, with positive results: 16 of 37 participants became abstinent from cigarettes after treatment.
We believe this article is a unique contribution to the literature on neuromodulation and SUDs for the following reasons: (1) We calculate effect sizes of individual studies across modalities and SUDs in order to identify areas of promise and gaps in the field; (2) We attempt to provide a systematic review of this topic, with clear inclusion and exclusion criteria for the reviewed studies, and; (3) we included several new studies on brain stimulation and SUDs which have been published since the review by Salling and Martinez. 4 
Limitations of the Current Review
There are certain limitations of the current review. First, the total number of studies examining the effects of brain stimulation techniques within each SUD is highly variable. Accordingly, the effectiveness of different neuromodulation techniques on certain SUDs should be considered preliminary. Second, there are several gaps in the literature that are worth noting, including: the lack of systematic study of optimal brain stimulation parameters in SUDs, lack of combination studies with approved pharmacological, and behavioral treatments, and a paucity of studies in co-morbid psychiatric and medical disorders.
CONCLUSIONS
In conclusion, the use of neuromodulation techniques (rTMS, tDCS, DBS) may be a promising treatment option for SUDs. Nonetheless, there is a need for further empirical data in this emerging field, which is particularly important given the high rates for relapse and poly-substance use in this vulnerable population.
